Jun 12, 2019 • 7:05 am EDT Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
May 29, 2019 • 8:05 am EDT Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June
May 28, 2019 • 8:05 am EDT Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting
May 15, 2019 • 8:05 am EDT Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May
May 9, 2019 • 7:00 am EDT Corbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates
May 2, 2019 • 12:00 pm EDT Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
May 1, 2019 • 8:05 am EDT Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019
Apr 18, 2019 • 8:05 am EDT Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA